In the 2009 CCSG competing renewal, ?Developmental Funds? received a merit descriptor of ?outstanding to exceptional? noting that the use of the funds was extraordinary in terms of the quality of recruitments and leveraging of the developmental funds to the Center's mission. During the current funding period, the OSUCCC benefited from $1,625,283 of CCSG Developmental Funds. For the $1,086,942 of CCSG dollars used for faculty and staff recruitment, the return to-date in total direct costs for CCSG-approved peer-reviewed extramural funding is $45,841,496, a 42:1 return on investment, and in total funding was $47,389,764, a nearly 44:1 return on investment. In addition, we used CCSG funds in the development of two needed and well utilized Shared Resources (SRs), the Medicinal Chemistry SR and the Nutrient and Phytochemical SR, both of which have now transitioned from developing to full Shared Resources and are presented in this application. In the new funding period, we request $2,000,000 in CSSG Developmental Funds over 5 years and propose using this support to continue to focus on building and innovating within our three traditional areas strength: genetics, experimental therapeutics, and prevention. Specifically, we propose to identify and recruit 18 senior, midlevel and junior faculty whose scientific expertise targets relevant needs in the OSUCCC strategic plan and/or catchment area. Further, we propose the development of two shared resources, Solid Tumor Translational Science and the Veterinary Clinical Research Support, that are innovative and necessary to support the science of the Research Programs and their individual member investigators.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Rolfo, Christian; Mack, Philip C; Scagliotti, Giorgio V et al. (2018) Liquid Biopsy for Advanced Non-Small Cell LungĀ Cancer (NSCLC): A Statement Paper from theĀ IASLC. J Thorac Oncol 13:1248-1268
Ren, Yulin; Gallucci, Judith C; Li, Xinxin et al. (2018) Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens. J Nat Prod 81:554-561
McDonald, J Tyson; Kritharis, Athena; Beheshti, Afshin et al. (2018) Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. Oncotarget 9:22693-22702
Nguyen, Phuong; Wuthrick, Evan; Chablani, Priyanka et al. (2018) Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. Am J Clin Oncol 41:140-146
Elchuri, Sailaja V; Rajasekaran, Swetha; Miles, Wayne O (2018) RNA-Sequencing of Primary Retinoblastoma Tumors Provides New Insights and Challenges Into Tumor Development. Front Genet 9:170
Reiff, Sean D; Muhowski, Elizabeth M; Guinn, Daphne et al. (2018) Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Blood 132:1039-1049
Nabar, Gauri M; Mahajan, Kalpesh D; Calhoun, Mark A et al. (2018) Micelle-templated, poly(lactic-co-glycolic acid) nanoparticles for hydrophobic drug delivery. Int J Nanomedicine 13:351-366
Tang, Xiaowen; Yang, Lin; Li, Zheng et al. (2018) First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res 8:1083-1089
Lai, Xiulan; Stiff, Andrew; Duggan, Megan et al. (2018) Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proc Natl Acad Sci U S A 115:5534-5539
Reeves, Katherine W; Pennell, Michael; Foraker, Randi E et al. (2018) Predictors of vasomotor symptoms among breast cancer survivors. J Cancer Surviv 12:379-387

Showing the most recent 10 out of 2602 publications